United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib capsules are indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for the management of primary dysmenorrhea [see clinical studies (14.5) ] celecoxib capsules are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see warnings and precautions (5.7, 5.9) ]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been reported in such patients [see warnings and precautions (5.7, 5.8) ].

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib capsules are indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for the management of primary dysmenorrhea [see clinical studies (14.5) ] celecoxib capsules are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see warnings and precautions (5.7, 5.9) ]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been reported in such patients [see warnings and precautions (5.7, 5.8) ].

United States - English - NLM (National Library of Medicine)

sydon labs llc - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see warnings and precautions (5)] celecoxib is incelecoxib is indicated for relief of the signs and symptoms of oa [see clinical studies (14.1)] celecoxib is indicated for relief of the signs and symptoms of ra [see clinical studies (14.2)] celecoxib is indicated for relief of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3)] celecoxib is indicated for the relief of signs and symptoms of as [see clinical studies (14.4)] celecoxib is indicated for the management of ap in adults [see clinical studies (14.5)] celecoxib is indicated for the treatment of pd [see clinical studies (14.5)] celecoxib is contraindicated: • in patients with known hypersensitivity to celecoxib, aspirin, or other nsaids. • in patients who have demonstrated allergic

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib capsules  are indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for the management of primary dysmenorrhea [see clinical studies (14.5) ] celecoxib is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see   warnings and precautions ( 5.7 , 5.9 )] . - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been reported in such patients [see warnings and precautions ( 5.7 , 5

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib capsules are indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for the management of primary dysmenorrhea [see clinical studies (14.5) ] celecoxib capsules are contraindicated in the following patients: pregnancy category c. pregnancy category d from 30 weeks of gestation onward. risk summary use of nsaids, including celecoxib capsules, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including celecoxib capsules, in pregnant women starting at 30 weeks of gestation. there are no adequate and well-controlled studies of cele

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib is contraindicated in the following patients : pregnancy category c. pregnancy category d from 30 weeks of gestation onward. risk summary use of nsaids, including celecoxib, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including celecoxib, in pregnant women starting at 30 weeks of gestation. there are no adequate and well-controlled studies of celecoxib in pregnant women. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2–4% for major malformations, and 15–20% for pregnancy loss. in animal reproduction studies, embryo-fetal deaths and an increase in diaphragmatic hernias were observed in rats administered celecoxib daily during the period of organogenesis at oral doses approximately

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib capsules are indicated for the management of the signs and symptoms of oa [ see clinical studies ( 14.1) ] for the management of the signs and symptoms of ra [ see clinical studies ( 14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [ see clinical studies ( 14.3) ] for the management of the signs and symptoms of as [ see clinical studies ( 14.4) ] for the management of acute pain in adults [ see clinical studies ( 14.5) ] for the management of primary dysmenorrhea [ see clinical studies ( 14.5) ] • celecoxib capsules are contraindicated in the following patients: known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug produc

United States - English - NLM (National Library of Medicine)

direct_rx - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - warning: risk of serious cardiovascular and gastrointestinal events cardiovascular thrombotic events • nonsteroidal anti-inflammatory drugs (nsaids) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. this risk may occur early in the treatment and may increase with duration of use. [see warnings and precautions (5.1)] • celecoxib capsules are contraindicated in the setting of coronary artery bypass graft (cabg) surgery. [see contraindications (4) and warnings and precautions (5.1)] gastrointestinal bleeding, ulceration, and perforation • nsaids cause an increased risk of serious gastrointestinal (gi) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. these events can occur at any time during use and without warning symptoms. elderly patients and patients with a prior history of peptic ulcer disease and/or gi bleeding are at greater risk for serious gi e

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib capsules are indicated for the management of the signs and symptoms of oa [see clinical studies (14.1)] for the management of the signs and symptoms of ra [see  clinical studies (14.2)] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3)] for the management of the signs and symptoms of as [see clinical studies (14.4)] for the management of acute pain in adults [see  clinical studies (14.5)] for the management of primary dysmenorrhea [see clinical studies (14.5)] celecoxib is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see warnings and precautions (5.7, 5.9)]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been reported in such patients [see warnings and precautions (5.7

United States - English - NLM (National Library of Medicine)

direct_rx - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib capsules are indicated 1.1 osteoarthritis (oa) for the management of the signs and symptoms of oa [see clinical studies (14.1)] 1.2 rheumatoid arthritis (ra) for the management of the signs and symptoms of ra [see clinical studies (14.2)] 1.3 juvenile rheumatoid arthritis(jra) for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3)] 1.4 ankylosing spondylitis (as) for the management of the signs and symptoms of as [see clinical studies (14.4)] 1.5 acute pain for the management of acute pain in adults [see clinical studies (14.5)] 1.6 primary dysmenorrhea for the management of primary dysmenorrhea [see clinical studies (14.5)] celecoxib capsules are contraindicated in the following patients: known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see warnings and precautions (5.7, 5.9)]. history of asthma, urticaria, or other allergic-type reactions after taking aspir